MAX
Company Analysis Celldex Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (16.28%) is higher than the sector average (-43.9%).
- Current debt level 0.48% is below 100% and has decreased over 5 years from 1.48%.
Disadvantages
- Price (23 $) is higher than fair price (22.53 $)
- Dividends (0%) are below the sector average (0.54%).
- The company's current efficiency (ROE=-26.84%) is lower than the sector average (ROE=104.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Celldex Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.4% | -25.7% | -1.5% |
| 90 days | -16.4% | -49.5% | 0.7% |
| 1 year | 16.3% | -43.9% | 13.2% |
CLDX vs Sector: Celldex Therapeutics, Inc. has outperformed the "Healthcare" sector by 60.18% over the past year.
CLDX vs Market: Celldex Therapeutics, Inc. has outperformed the market by 3.08% over the past year.
Stable price: CLDX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CLDX with weekly volatility of 0.31% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (23 $) is higher than the fair price (22.53 $).
Price is higher than fair: The current price (23 $) is 2% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-10.19) is lower than that of the sector as a whole (33.29).
P/E vs Market: The company's P/E (-10.19) is higher than that of the market as a whole (-108).
5.3. P/BV
P/BV vs Sector: The company's P/BV (2.17) is lower than that of the sector as a whole (254.5).
P/BV vs Market: The company's P/BV (2.17) is lower than that of the market as a whole (83.29).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (230.43) is higher than that of the sector as a whole (129.32).
P/S vs Market: The company's P/S indicator (230.43) is higher than that of the market as a whole (115.88).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-8.3) is higher than that of the sector as a whole (-27.64).
EV/Ebitda vs Market: The company's EV/Ebitda (-8.3) is higher than that of the market as a whole (-92.19).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 24.47% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (24.47%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (241.72%).
6.4. ROE
ROE vs Sector: The company's ROE (-26.84%) is lower than that of the sector as a whole (104.5%).
ROE vs Market: The company's ROE (-26.84%) is lower than that of the market as a whole (-6.66%).
6.6. ROA
ROA vs Sector: The company's ROA (-25.1%) is lower than that of the sector as a whole (-2.18%).
ROA vs Market: The company's ROA (-25.1%) is lower than that of the market as a whole (37.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-25.76%) is lower than that of the sector as a whole (1.04%).
ROIC vs Market: The company's ROIC (-25.76%) is lower than that of the market as a whole (9.38%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.54%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
